share_log

Arqit Quantum Analyst Ratings

Benzinga Analyst Ratings ·  Feb 22, 2023 06:28
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
02/22/2023 614.29% HC Wainwright & Co. $14 → $10 Maintains Buy
12/22/2022 900% HC Wainwright & Co. $16 → $14 Maintains Buy
07/19/2022 400% Deutsche Bank → $7 Initiates Coverage On → Hold
04/26/2022 1042.86% HC Wainwright & Co. → $16 Initiates Coverage On → Buy

What is the target price for Arqit Quantum (ARQQ)?

The latest price target for Arqit Quantum (NASDAQ: ARQQ) was reported by HC Wainwright & Co. on February 22, 2023. The analyst firm set a price target for $10.00 expecting ARQQ to rise to within 12 months (a possible 614.29% upside). 4 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Arqit Quantum (ARQQ)?

The latest analyst rating for Arqit Quantum (NASDAQ: ARQQ) was provided by HC Wainwright & Co., and Arqit Quantum maintained their buy rating.

When is the next analyst rating going to be posted or updated for Arqit Quantum (ARQQ)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arqit Quantum, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arqit Quantum was filed on February 22, 2023 so you should expect the next rating to be made available sometime around February 22, 2024.

Is the Analyst Rating Arqit Quantum (ARQQ) correct?

While ratings are subjective and will change, the latest Arqit Quantum (ARQQ) rating was a maintained with a price target of $14.00 to $10.00. The current price Arqit Quantum (ARQQ) is trading at is $1.40, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment